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Computers allow describing the progress of a disease using computerized models. These models allow
aggregating expert and clinical information to allow researchers and decision makers to forecast disease
progression. To make this forecast reliable, good models and therefore good modeling tools are required.
This paper will describe a new computer tool designed for chronic disease modeling. The modeling capa-
bilities of this tool were used to model the Michigan model for diabetes. The modeling approach and its
advantages such as simplicity, availability, and transparency are discussed.
 2010 Elsevier Inc. All rights reserved.1. Introduction
Chronic diseases have a signiﬁcant impact on national health. A
chronic disease such as diabetes may develop over a long time per-
iod and may involve many complications. Conducting longitudinal
clinical trials to cover such long periods of time is a difﬁcult task
from practical reasons. This is one reason why computer models
are gaining popularity.
Perhaps the best sign for this increase in popularity is the diver-
sity of diseasemodels that can be found in the literature [1]. Another
sign for the popularity is the need for propermodeling guidelines for
general disease modeling [2], and speciﬁcally for diabetes [3].
Diabetes models are evaluated during the Mount Hood confer-
ence [4]. This is a main stage for models to be compared and con-
trasted. Yet, even in such environments, comparing models is
difﬁcult since models are not necessarily accessible. Accessibility
to researchers varies between proprietary models, where little is
known about internals, to full transparency where the model struc-
ture and software tools are available for researchers. This varied
access is shown on notable models from the Mount Hood
conference.
For example, the Archimedes model [5–7] is commercial and
proprietary, which makes it less accessible to researchers. In con-
trast, the software for the Centers for Disease Control and Preven-
tion/Research Triangle Institute (CDC/RTI) model [8] is not
published, yet the model is described in details in their technicalll rights reserved.
iostatistics, School of Public
I, 1415 Washington Heights,
5.
jmisaman@umich.edu (D.J.M.
(D. Lee).
. Barhak).report [9]. The Eagle simulation model [10] is also available upon
request as a technical report [11]. The global diabetes model also
reveals modeling equations in [12]. The United Kingdom Prospec-
tive Diabetes Study (UKPDS) Outcomes Model [13] is even more
accessible: not only it is described in details in their publications;
it is also provided as software that can be requested through their
web site http://www.dtu.ox.ac.uk/outcomesmodel/index.php. The
most accessible diabetes model to date, however, is the Michigan
model for diabetes. It is the most transparent one since it is fully
documented, and upon accepting the license terms it is freely
available for download from the web site http://www.med.umi-
ch.edu/mdrtc/cores/DiseaseModel/model.htm.
Even with accessible models, often a user would like the ability
to modify it at some point. Thus, a basic and necessary requirement
from the software is to allow manipulation of model parameters.
However, the ability to easily modify the structure (topology) of
the disease model, or the ability to create new disease processes
using the same software tool are more advanced, and therefore
typically overlooked. For example, the models mentioned above
such as the UKPDS model or the CDC/RTI model do not describe
how a new disease process can be added or removed. Even these
publicly assessable disease model software tools do not focus on
providing a modeling environment that allows manipulating the
structure of the disease model.
In this paper, we will present disease modeling software that
provides a platform where users can deﬁne the structure and the
parameters to implement their disease models. This general mod-
eling environment includes a Graphical User Interface (GUI), model
parameter estimation software, and a simulation compiler, and it is
published freely with open source under General Public License
(GPL). This set of modeling tools allows users to run, modify, esti-
mate, and create new models using the same set of tools.
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pliﬁed modeling approach based on state transitions and a free
modeling environment to facilitate increased human capabilities
with regards to creating disease models. These capabilities, which
are based on state transitions, are intuitive for humans to work
with [14].
In this paper we will describe the modeling software environ-
ment and demonstrate important features in it. We will provide
several examples regarding the usefulness of this modeling envi-
ronment with regards to the Michigan model for diabetes.2. Supported disease model
The Michigan model has been previously published and vali-
dated against Wisconsin Epidemiological Study of Diabetic Reti-
nopathy (WESDR) data in [15]. At that time, the Model did notTermina
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Fig. 1. The Michigan model for diabetes. IGT means impaired glucose tolerance,use the advanced modeling environment described in this paper.
Recently the model has been updated and validated against UKPDS
published results [16]. During its update the model has been gen-
eralized and our modeling software was developed to support this
generalization. This generalization not only allows users to modify
the Michigan model for diabetes, but also allows modeling of other
disease models with similar structures. These modeling capabili-
ties are therefore described with speciﬁc examples from the Mich-
igan model that is shown in Fig. 1.
The Michigan model is a state transition model that generalizes
the Markov model. Each state in the model (marked as boxes in
Fig. 1) is associated with a stage of disease progression. Progression
of the disease is modeled as transitions between states (marked as
arrows in Fig. 1) and each transition can be assigned with speciﬁc
transition probabilities. The Michigan model is a discrete time
model using a preset constant time step (usually 1 year) to time
transitions between states. The modeling environment, however,Sub-process 
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ESRD means end stage renal disease, and MI means myocardial infarction.
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for disease modelers, and are part of our simpliﬁed approach and
are discussed hereafter.
2.1. Instantaneous event states
The Michigan model allows deﬁning states that take no time to
pass through. The need of such instantaneous states has been rec-
ognized by other models such as the CDC/RTI model. In Fig. 1 these
states are represented as rhombuses and include the states of
Stroke or Myocardial Infraction (MI). Such states represent an
event that occurs and immediately passes, rather than a state that
an individual can occupy at the end of a simulation time step.
Therefore transition probabilities leading out of an event state
sum to 1. The existence of these states does not change the Markov
property since an equivalent Markov model can be constructed
without using event states. However, the existence of these states
makes it easy for the modeler to indicate an event and model event
recurrence and therefore the introduction of such states is useful
for interactive human modeling.
2.2. Nested sub-processes
Modeling of diseases requires focusing on more than one dis-
ease process. This is demonstrated with regards to the diabetes
model. Looking at Fig. 1, one can recognize processes such as car-
diovascular disease, nephropathy, cerebrovascular disease, reti-
nopathy, and neuropathy. These are all related to diabetes, yet
each sub-process has distinct states not shared with other pro-
cesses. Furthermore, disease progression may be independent in
each sub-process. For example an individual can progress from an-
gina to an MI (Myocardial Infarction) to survive MI, and at the
same simulation step progress from clinical neuropathy to ampu-
tation while staying in a state of No-Retinopathy. This example
demonstrates the process in terms that are relatively easy for a hu-
man to comprehend.
An alternative way to model such progression is using an equiv-
alent Markov model that is composed of aggregate states such as
No Cardivascular Disease + No Nephropathy + No Cerebrovascular
disease + Blindness + No Neuropathy. However, this is not intuitive
to the user since the number of different states will be too large,
and their description too long to effectively manage. Moreover,
deﬁning transition probabilities would be non-intuitive and
cumbersome.
For these reasons, we are deﬁning sub-processes that can
each progress independently during simulation. These sub-pro-
cesses are marked with dashed outline boxes. Each sub-process
can be a Markov model containing states and transitions of its
own. A set of parallel sub-processes is initiated by progressing
to a splitter state marked as a dot in Fig. 1. When an individual
reaches a splitter state in the model, multiple sub-processes are
initiated and the subject is placed in the ﬁrst state in each of
these sub-processes. To maintain fairness each of these sub-pro-
cesses are processed in random order during simulation and the
combination of states in the sub-processes deﬁnes the condition
of the individual. The individual progresses in parallel through
each of these sub-processes as long as none of these sub-pro-
cesses are exited. Exiting a sub-process means collapsing all par-
allel sub-processes and proceeding to a joiner state that is also
marked as a dot in Fig. 1. Collapsing sub-processes is usually
associated with death and therefore the need to stop and col-
lapse all parallel sub-processes. Note that a joiner state is always
associated with a splitter state. It is enough to reach the joiner
state by exiting one sub-process to collapse all parallel sub-pro-
cesses starting from the same splitter state. This includes sub-
processes that usually will not lead to the joiner state that aremarked as a dashed arrow in Fig. 1, e.g. reaching ESRD death
will result in ending the retinopathy sub-process, and collapsing
all sub-processes to diabetes death through a joiner state.
Joiner and splitter states are artiﬁcial states treated as instanta-
neous states. Their deﬁnition allows encapsulating a set of sub-
processes as if they were a single state. Therefore it is possible to
nest sub-processes within one another. In Fig. 1, for example, the
neuropathy sub-process is encapsulated within the diabetes sub-
process, meaning that this is diabetic neuropathy as opposed to
general neuropathy that may or may not be associated with diabe-
tes. This treatment of sub-processes allows breaking processes
within a disease to a ﬁner level of detail dealing with more speciﬁc
disease complications while maintaining a hierarchical structure
that is more intuitive for modeling purposes. This use of sub-pro-
cess capabilities can lead to concurrent modeling of multiple dis-
eases in the future. In a sense our diabetes model already does
this to some degree, since it includes several disease processes al-
ready. Yet the focus of the model is still diabetes and parallel pro-
cesses were modeled using information from diabetics.
Yet even within diabetes, we are already modeling dependen-
cies between sub-processes. This is accomplished using the meth-
ods described in the next section.
2.3. Transition probabilities dependant on parameters
Our diabetes model addresses individual characteristics such as
age and gender. This is made possible by allowing the user to de-
ﬁne transition probabilities as functions of various parameters.
These functions can be general mathematical expressions using
mathematical, Boolean, and equality operators, and a set of math-
ematical functions such as exp, log, min, max etc. As will be shown
later, these functions can also include conditional statements (sim-
ilar to an ‘‘if” statement in a programming language).
Each such expression may involve one or more parameters that
can represent various individual and system characteristics. Below
is a list of relevant parameter types the system supports:
 Covariates: these are parameters representing general individ-
ual characteristics such as age and gender.
 State indicators: indicating if the individual is in a certain state/
sub-processes. There are several types of state indicators for
each state: the entered state indicator indicates if a state was
ﬁrst entered in this simulation step; the diagnosed state indica-
tor indicates if the state was diagnosed which may be different
than the actual state the individual is in; the treated state indi-
cator representing that the individual is treated for this state;
and the complied state indicator speciﬁes if the individual com-
plied with the treatment. Note that the computer automatically
assigns values to the actual and entered state indicators
whereas the user controls the values of the diagnosed, treated,
and complied state indicators.
 Intervention parameters: additional parameters beyond diag-
nosed, treated, and complied state indicators associated with
interventions. For example, compliance rate to treatment.
 Cost and quality of life parameters: parameters such as yearly
costs or health utility score that reﬂect costs of treatment and
the quality of life of individuals.
 User deﬁned functions: these are expressions composed of
other parameters saved under a parameter name. These user
deﬁned functions can later be used in other expressions to sim-
plify and shorten the text. The system is responsible for expand-
ing the functions within the expression similar to a substitution
of a mathematical expression.
The use of such parameters in transition probabilities can gov-
ern the progression of an individual in the model. For example in
794 J. Barhak et al. / Journal of Biomedical Informatics 43 (2010) 791–799our model the transition from no-cerebrovascular disease to a
stroke is heavily based on the UKPDS 60 risk engine [17]. The
UKPDS part of the expression is:
1.0 - Exp(- 0.00186  1.092(AgeAtDiagnosisOfDiabe-
tes-55)  0.700IsFemale  1.547Smoke  8.554AF
1.122((SBP - 135.5)/10)  1.138(LipidRatio - 5.11)
1.145(DurationOfDiabetes))),
where AgeAtDiagnosisOfDiabetes, Male, Smoke, AF (Atrial ﬁbril-
lation), and SBP (Systolic Blood Pressure) are covariates associated
with the individual; IsFemale is a user deﬁned function deﬁned as
1-Male that converts our deﬁnition of the Male covariate to the
UKPDS usage of gender in the formula. DurationOfDiabetes is de-
ﬁned as Age-AgeAtDiagnosisOfDiabetes. And LipidRatio is deﬁned
as TotalCholesterol/HDLCholesterol.
The formula above is an example of a continuous function
depending on parameters that govern the transition probability.
However, our modeling system also supports conditional transi-
tion probabilities. These can be accomplished by using the
Table and Iif functions.
The Iif function stands for ‘‘immediate if” and is similar in struc-
ture to other languages. This function gets three arguments (1) The
conditional expression, usually a Boolean expression where 0
means a false conditional; (2) a value/expression to be returned
in case of a true conditional; (3) a value/expression to returned
in case of a false conditional. For example, the transition probabil-
ity between Survive Stroke and Death is governed by the formula:
Iif(Diabetes_with_treatment_by_Insulin, 0.0148,
0.0166),
where Diabetes_with_treatment_by_Insulin is a state indicator
deﬁning the desired treatment level. If the person is in a diabetes
state that requires taking insulin, the transition probability will
be 0.0148, otherwise it will be 0.0166. Note that the system would
have accepted more elaborate expressions for the true and false
values. This includes additional Iif statements to other functions
allowing the creation of a complicated decision tree to calculate
transition probabilities.
To further aid in creating complicated conditional statements,
the system can use the Table function. This function allows deﬁn-
ing a multi-dimensional table that can be accessed by one or more
parameters to retrieve the value associated with the value in the
parameter domain. For example, the probability of a diabetic to
die after surviving MI is governed by the following table:
Table(3, 2,2,5, 0.0156,0.0156,0.0156,0.0156,0.0156,
0.0013,0.006,0.0116,0.0193,0.0193,0.0034,0.0034,0.0089,-
0.0133,0.0133,0.0034,0.0034,0.009,0.0131,0.0131, Type_2_
Diabetes,NaN,0,1, Male, NaN, 0, 1, Age, 0,24.999,54.999,
64.999,74.999, 100)
where the initial 3, colored in red, indicates the number of
dimensions, then the three next numbers 2,2,5, indicated in green,
are the sizes of the dimensions that deﬁne the array. The next
225 = 20 numbers, indicated in blue, are the data to populate
the table. Finally, the dimension names and their ranges are de-Table 1
Example of a multi-dimensional table as deﬁned by the system.
Male 6 0 0 < Male 6 1
Type_2_Diabetes 6 0 0 < Age 6 24.999 0.0156 0.0013
24.999 < Age 6 54.999 0.0156 0.006
54.999 < Age 6 64.999 0.0156 0.0116
64.999 < Age 6 74.999 0.0156 0.0193
74.999 < Age 6 100 0.0156 0.0193
0<Type_2_Diabetes 6 1 0 < Age 6 24.999 0.0034 0.0034
24.999 < Age 6 54.999 0.0034 0.0034
54.999 < Age 6 64.999 0.0089 0.009
64.999 < Age 6 74.999 0.0133 0.0131
74.999 < Age 6 100 0.0133 0.0131ﬁned – these represent the table headers. Table 1 shows how this
table would look like using a more intuitive depiction. Note that
this table handles both continuous parameters and discrete param-
eters using the same representation.
Using such table deﬁnitions, it is possible to relatively easily
specify transition probabilities that depend on multiple continuous
or discrete parameters and includes ranges. This is a common way
information appears in the literature, which is where our informa-
tion comes from, and therefore a relatively intuitive way to deﬁne
transition probabilities avoiding a complicated and a long set of Iif
statements.
Note that parameters which control the transition probabilities
may hold historical information derived from state indicators or
previously generated random numbers. In general, this invalidates
the Markov property of being memory-less and the model may no
longer be a Markov model. Yet, since dependency on historical
events is important when describing disease progression, and since
the Markov model is intuitive, our model is a compromise between
the two. We tried to maintain the intuitive part of a state transition
model while allowing the user to create dependencies on memory.
This compromise methodology no longer allows us to calculate dis-
ease progression using matrix representation and multiplication as
it is traditional with a Markov model. Instead we have to use
Monte Carlo simulation as explained in the next section.
2.4. Monte Carlo simulation with rules
Choosing Monte–Carlo for simulation allows extending the
model even further by adding additional rules before and after
each time step in the Markov model. Fig. 2 represents the ﬂow dia-
gram of the simulation and the new rules. The simulation is com-
posed of three nested loops:
The outermost loop is the repetition loop that repeats the same
simulation many times. Each repetition generates potentially dif-
ferent results due to the random nature of a Monte Carlo simula-
tion. After collecting these different results, mean values and the
distribution characteristics of the results can be determined. A
large number of repetitions will statistically decrease the uncer-
tainty created by the randomness of the Monte Carlo simulation
at the price of longer execution times. This tradeoff of calculation
time and uncertainty has to be balanced by the modeler.
The second nested loop is the individual loop that iterates
through individuals in the simulation population. This baseline
population deﬁnes initial parameter values to be used for each
individual. For example the age, gender, and smoking status of
an individual are loaded as the initial value of these parameters be-
fore starting the time loop.
The innermost nested loop is the time loop that handles the
changes in the parameters and states. In this loop the disease pro-
gression occurs for each individual. Note that only the box titled
‘‘Phase 2: calculate complications” corresponds directly to the ex-
tended Markov model seen in Fig. 1, the rest of the boxes represent
sets of rules to be applied as pre-processing or post-processing
terms. Simulation rules can be considered as general programming
statements and are of the following form:
If Individual is in [Rule State] then:
If random number < [Occurrence Probability Threshold] then:
[Affected parameter] = [Given formula]where the modeler
can deﬁne the rule arguments marked with brackets. This allows
the user easy control of parameters before and after the Markov
model is processed. The [Rule State] argument represents a state
indicator and defaults to ‘‘all states”. The [Occurrence Probability
Threshold] argument deﬁnes a threshold to control the random
execution of the rule and defaults to 1. The [Affected Parameter]
argument holds the name of the parameter that its value will
change. The [Given Formula] argument holds an expression that
Repetition Loop 
Individual Loop 
Time Loop 
Phase 1: Update Covariates 
Phase 3: Update Intervention 
Phase 2: Calculate Complications 
Phase 4: Update Costs / Quality Of Life 
Tim
e =Tim
e +1 
Load Individual Initial Data 
N
ext Individual 
Extended 
Markov 
Model 
Post-
Processing i  
using rules 
Repetition = 0 
R
epetition = R
epetition + 1 
Pre-
Processing 
using rules 
Fig. 2. Flow diagram of the Monte–Carlo simulation.
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ceive if the conditional parts of the rule are valid.
A rule, for example, can indicate the increase in age every year
as in:Age ¼ Ageþ 1
A rule can also be more complicated. For example, in diabetes
modeling, glycated hemoglobin (HbA1c or A1c for short) is an
underlying physiologic measurement used in many cases to diag-
nose diabetes and classify its severity. Our model simulates A1c
progression in people without diabetes using a probabilistic
bounded increase in a variable named A1c using the following rule:
If Individual is in No_Diabetes then:
If random < 0.03 then:
A1c = Min((A1c + 0.68),15)
Note that the expression is general and may contain mathemat-
ical operations and functions, other parameters, and even condi-
tional Table and Iif functions. This allows the user to change the
model in a general way.
Although the rules are general, the system structures the mod-
eling tasks by deﬁning different phases of rule application. These
phases limit the type of parameters that can be used as the [Af-
fected parameter]. Phase 1 allows the update of covariates such
as age or A1c. Phase 2 executes a single simulation step in the pre-
viously described extended Markov model. Phase 3 limits the up-
date to diagnosed, treated, and complied state indicators and to
intervention parameters. Phase 4 is limited to updating cost and
quality of life parameters.
These limitations follow the following reasoning: At the
beginning of the year the individual characteristics are updated.
Then the disease progresses according to these new characteris-
tics using the extended Markov model. Then the individual is
diagnosed and treated for new conditions. Finally the cost of
treatment and the individual’s quality of life is determined. Then
the same cycle can be repeated for the next year within the time
loop. This simulation is repeated for each individual in the indi-
vidual loop. Finally, the entire population undergoes the simula-
tion in the repetition loop. Results can then be analyzed using
additional tools described in the next section.3. System capabilities
A software tool was developed allowing chronic disease model-
ing similar to the Michigan model for diabetes. The system sup-
ports the following features:
 Parameter storage: The system allows storage of multiple
parameters that are used within the system, including multi-
dimensional tables that can be accessed using another parame-
ter deﬁned in the system. The user can deﬁne the parameter
name, its type, and validation rules to be observed during sim-
ulation. Validation rules may restrict parameter values to be
integer, general numbers, matrix/vector, tables, or general
expressions. Validation rules may also include maximal and
minimal bounds on the parameter value. Validation rules are
important in increasing the programmatic integrity of the
model and can be used as a simple model debugging tool, espe-
cially with larger models where the chance for human error
increases. This validation feature proved to be essential during
the development of the Michigan model for diabetes.
 Storage of multiple disease models: The system can hold multiple
disease models deﬁned by states, sub-processes and transition
probabilities. Different models can share states and therefore
allows building a model using common terminology. This also
allows maintaining several versions of the same model in the
system at the same time. This has proved to be a useful option
during earlier development stages where there is a lot of uncer-
tainty and therefore several model versions.
 Storage and Manipulation of multiple population sets: The system
allows storing population cohort information as a snapshot of
the individual characteristics. The system can support storage
of multiple such population sets, each can be later used to ini-
tialize simulation parameters. Note that population sets are
stored separately from the models to allow simulating a model
with different population sets or the same population set with
different models. The system allows importing these population
sets from comma separated values text ﬁles. The system also
supports deﬁnition of population sets as distributions and
expressions. Such distribution-based populations allow describ-
ing a population set in a similar way populations are described
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new data-based population set by random generation. This
capability allows imitation of study populations from publicly
available data, without the need to access propriety data gath-
ered by this study. This allows independent modeling as expe-
rienced in our diabetes model. For example, we did not need
access to the UKPDS dataset during validation, the UKPDS pub-
lication [16] that can be found in the literature was sufﬁcient.
Note that similar population generation mechanism is provided
by the global diabetes model [12]. However, that generator is
limited to a certain set of studies and complications and does
not allow correlation between complications. In contrast, our
population generation method is general and a population can
be deﬁned by a set of expressions that can depend on other pop-
ulation parameters, e.g. the age distribution can depend on gen-
der in our method and the same is true for disease states.
 Storage of simulation projects: A simulation project is deﬁned by
a combination of a model, a population set, simulation rules,
and some other simulation parameters. Combining these
together with clerical information allows deﬁning different sim-
ulation projects that can explore different situations of interest.
This option was useful when a single parameter, such as com-
pliance level to treatment, was changed between different sim-
ulations and we needed to compare results between these
projects.
 Simulation execution and storage of its results: The system can
compile the project into a Python program that is run to gener-
ate simulation results. These results are then loaded back to the
system to be stored with association to the simulation project.
The use of Python as a programming language allowed debug-
ging simulation programs with external Python tools, while still
maintaining readable text pertaining to the disease model.Fig. 3. An example of the project form. This form allows deﬁning the model and populati
steps and the number of repetitions. The form allows manipulating rules according to
convenience of the user. Model parameter estimation: Beyond simulation, the system is
capable of model parameter estimation for a single Markov pro-
cess using a maximum likelihood technique. This technique
allows gathering summary data from the publicly available lit-
erature and using it to estimate model parameters of a single
sub-process. The model parameter estimation method is
described in further details in [18,19]. The implementation of
the estimation method was accomplished using the Python
with the Scipy optimization library that allows constrained
optimization routine [20,21]. The Estimation Technique is also
freely available online as a Matlab Prototype as the project
web site: http://www.med.umich.edu/mdrtc/cores/Disease-
Model/software.htm.
 Storage of the data as ﬁles: The system is currently a standalone
system and allows maintaining all the above entities in a ﬁle.
The system allows minimal version control of its saved ﬁles.
This has been sufﬁcient so far; however, future development
is geared towards shared environment by multiple users.
 Graphic User Interface (GUI): The system can be controlled using
forms and reports based onWxPython that enable management
of the above entities. The form system allows drilling down the
information hierarchy to locate and edit details of interest. For
example double clicking the model in the project page will
pop up the model form and then clicking on the main process
of the model will bring the states form with the appropriate
process deﬁnition and so forth. The GUI also supports the use
of a cost wizard that aids with calculating cost and quality of life
in phase 4 of the simulation. Fig. 3 shows the project form to
demonstrate how the system handles easy deﬁnition of rules.
This GUI proved extremely useful when developing our diabetes
model. The ability to visually access the model allowed quicker
and easier modeling by the human. Just to give an idea of theon set to be used as well as simulation parameters such as the number of simulation
their phase in the simulation. Each phase is displayed in a different tab for the
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described as a document is about 40 pages long. Whereas using
the GUI we reach each parameter with several guided clicks and
perform controlled changes accompanied with feedback. For
example, when a user types in a bad expression, the GUI will
raise an error correcting the user. This syntax check was useful
to ﬁlter out human errors in our diabetes model. Even during
development, once our GUI was operational, many testing tasks
were modeled using the GUI and exported back as code since
the human user found it easier than coding.
The described system was tested using several case scenarios
that test its expression, simulation and other capabilities. The test
suite for the software, the source code, the user documentation,
and the developer documentation, are all published freely. The sys-
tem is published under GPL license and can be obtained using the
following URL:
http://www.med.umich.edu/mdrtc/cores/DiseaseModel/
software.htm.4. Results
The utility of a system such as described in this paper depends
heavily on the feasibility and validity of the models used. To dem-
onstrate the system feasibility, we have created many simulation
tests that are published with the software. This ﬁrst level of valida-
tion demonstrates correctness and serves for quality assurance.
To demonstrate applicability to disease modeling, we have
developed the Michigan model for diabetes using our software
framework. This model includes 7 disease sub-processes with
about 30 states and about 50 transitions as seen in Fig. 1. More
than 100 variables and more than 100 simulation rules are used
by this model. The model went throughmore than 30 versions dur-
ing its development process. The development process included
the following stages: (1) literature review; (2) model formulation;
(3) validation of our model against clinical study results. These
development stages were repeated until convergence to the pub-
lished model version was achieved. The model ﬁle titled ‘‘Michigan
model for diabetes 11-May-2009” can be downloaded from the
model section of web site using the following link:
http://www.med.umich.edu/mdrtc/cores/DiseaseModel/
model.htm.
This model ﬁle is a compressed archive that contains a docu-
mentation ﬁle that details the above development stages: (1) the
literature used to create the model is provided in the bibliography;
(2) the manual calculations used to extract the transition probabil-
ities from the literature are described in great detail so these can be
replicated by others; and (3) the model validation against the
UKPDS 33 results are summarized in more detail than will be pre-
sented below.
To allowmodel validation, a population of 1138 individuals was
artiﬁcially generated from distributions provided by the UKPDS33
population as described in Section 4. This population was used as aTable 2
Validation of Michigan model for diabetes simulation results after 10 years against results r
(SD), min, median, and max values from 100 repetitions. The relative error column compa
UKPDS 33 deﬁnition UKPDS 33 reported Michigan model sim
Mean S
Diabetes related deaths 129 135.35 9
All cause mortality 213 213.89 1
Myocardial Infarction 186 189.93 1
Stroke 55 48.17 6
Micro-vascular 121 101.72 8baseline population for the model simulation the results of which
were validated.
Model validation was conducted by repeating the model simu-
lation for 100 times. The simulation process took about 18 hours
on 4 processor cores (about 3 days on a single processor core). At
the end of the simulation process, a large array of records was gen-
erated. Each record contained the values of all model parameters
for each person in each living year for each repetition. An example
of such output is presented in Appendix A. These simulation results
were analyzed and compared against UKPDS 33 results appearing
in [16].
Table 2 shows selected simulation results compared to UKPDS
33 aggregate results. This validation shows a good ﬁt in most cat-
egories. The micro-vascular category, as deﬁned by UKPDS 33 [16],
includes elements from the retinopathy process, which we recog-
nize needs improved modeling. This is an area of active research.
Our diabetes model used parameters based on the UKPDS. For
example, we calculated death rates from MI based on published
rates in the UKPDS 33. Simulation results were tabulated to com-
parable summary measures as reported in ﬁgure 4 in [16].
Our report engine allowed proper counting of incidences and of
persons affected by incidences for each category for speciﬁed peri-
ods. More speciﬁcally, using our software, it is possible to count the
number of persons who had a stroke in the ﬁrst 10 years, or the to-
tal number of strokes in the population in the same time period.
Our framework also calculates statistics of repetitions. The results
in Table 2 were calculated using these mechanisms.
To allow further and more detailed scrutiny of our work, these
validation results along with a fully documented diabetes model
are available online at our web site.5. Discussion
Recent interest in disease forecast has resulted in a multitude of
disease models with competing strengths and weaknesses. For
example, most disease models are dedicated software tools in a
variety of languages that are developed for the sole purpose of sim-
ulating a speciﬁc disease model. The UKPDS outcomes model [13]
is embodied within an XL workbook, the global diabetes model
[12] is implemented in Visual Basic, and the eagle diabetes model
[10,11] is coded in C++.
These models use Monte Carlo simulation, which is the simula-
tion engine that is generalized and implemented by our software.
The CDC/RTI model was designed using a Markov model, which
our tool also allows. All of these tools are limited to diabetes; this
is reasonable considering the huge cost involved in developing the
model.
In contrast, the Archimedes model [5–7] is different from the
above models in that it uses an object oriented approach to model
progression of continuous variables. Archimedes has been pub-
lished extensively, yet being proprietary and of a different mathe-
matical framework, it is conceptually different than our open
framework.eported in UKPDS 33. The Michigan model results show the mean, standard deviation
res the highlighted columns using the following formula (mean – UKPDS)/UKPDS.
ulation results Relative error
D Min Median Max
.77 111 135 164 0.049
2.16 181 213 255 0.004
1.11 159 189 219 0.021
.21 32 48 63 -0.12
.98 80 101 132 -0.16
798 J. Barhak et al. / Journal of Biomedical Informatics 43 (2010) 791–799Similar to our framework, some diabetes models have an asso-
ciated GUI. The global diabetes model [12] has an interface that al-
lows deﬁning population parameters before simulation. Another
notable user interface is the Diabetes Ph.D. web site [22] that uses
the Archimedes simulation engine. However, these interfaces are
limited to managing values of model speciﬁc parameters and mod-
el structure can not be changed. It is also not possible to deﬁne a
new model using these user interfaces.
In contrast, our framework can accommodate and manipulate
multiple distinct models and it is not dedicated to a single model.
This is a major difference between our software framework and
other modeling tools. For example, our software can be used to de-
velop disease models other than diabetes. Furthermore, by modify-
ing our model structure, diabetes researchers can use our existing
diabetes model to project outcomes based on the results of their
own innovative research. We consider this to be an important ben-
eﬁt of our general simulation engine and GUI.
However, disease models are not limited to diabetes. During the
work on our project we encountered disease models and related
tools for various other diseases, including inﬂuenza [23], coronary
heart disease [24], and cancer [25]. This is just a partial list that
demonstrates the variety of dedicated tools available. To our
knowledge to date there is no other software framework that is
ﬂexible enough to accommodate multiple chronic disease models
that has the following capabilities: (1) the ability to deﬁne the
model structure, (2) the ability to deﬁne parameters and formulas,
(3) the ability to set simulation rules and perform simulation, (4)
and the ability to analyze the output data.
These simulation capabilities, offered by our framework are
general enough to model chronic diseases. Yet our framework is
not suitable for modeling infectious diseases since these require
interaction between individuals, which our framework does not
currently support. Also, our support does not extend to general
continuous time modeling as we are conﬁned by a constant length
simulation step. Since our simulation engine includes event states,
it already handles event queues, which can be extended further in
future research. Another gap in our framework is that our simula-Table 3
Sample output from simulation results. This table shows selected result columns (out of 11
the system before simulation. State indicator values are set to 1 if the individual is in tha
indicator.
Individual
ID
Repetition Time Age Male A1c Death_
Entered
Stroke_
Entered
No_CVD A
E
1 0 0 45.2 1 7.3842 0 0 1 0
1 0 1 46.2 1 8.1342 0 0 1 0
1 0 2 47.2 1 6.6342 0 0 1 0
1 0 3 48.2 1 6.6342 0 0 1 0
1 0 4 49.2 1 6.6342 0 0 1 0
1 0 5 50.2 1 6.6342 0 0 1 0
1 0 6 51.2 1 6.6342 0 0 1 0
1 0 7 52.2 1 6.6342 0 0 1 0
1 0 8 53.2 1 6.6342 0 0 1 0
1 0 9 54.2 1 6.6342 0 0 1 0
1 0 10 55.2 1 6.6342 0 0 1 0
2 0 0 37.8 1 7.2903 0 0 1 0
2 0 1 38.8 1 7.2903 0 0 1 0
2 0 2 39.8 1 8.0403 0 0 1 0
2 0 3 40.8 1 6.5403 0 0 1 0
2 0 4 41.8 1 6.5403 0 0 1 0
2 0 5 42.8 1 6.5403 0 0 0 1
2 0 6 43.8 1 7.0403 0 0 0 0
2 0 7 44.8 1 7.0403 0 0 0 0
2 0 8 45.8 1 7.5403 0 0 0 0
2 0 9 46.8 1 8.0403 0 0 0 0
2 0 10 47.8 1 8.0403 0 0 0 0
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
1138 0 6 61.6 1 6.2802 1 1 1 0tion capabilities are more advanced than the estimation capabili-
ties. Estimation of model parameters is currently conﬁned to a
Markov model in a single process. Expanding estimation capabili-
ties is currently a research topic of much interest. Possible research
directions include multiple sub-processes, and model expression
support. To allow others to participate in this research effort, we
are publishing our methodology [18,19], and we have published
our estimation source code both in Matlab and Python
environments.
Publishing the disease modeling software for free along with its
open source is compatible with the design of the modeling ap-
proach that uses simpler more intuitive techniques to model dis-
eases. These intuitive approaches reduce the learning curve for
researchers who are entering the ﬁeld. It also enables collaboration
between researchers specializing in different facets of a single dis-
ease. Finally, it enables researchers to develop new disease models
without recreating a GUI or a computation engine. The tool exists,
and clinical collaborators can focus their efforts on clinical matters
rather than technical matters.
Another advantage of our software framework is that with our
relatively simple modeling techniques, we support a wider human
comprehension of disease processes. Using standardized ‘‘base”
models of the natural history of disease, researchers can incorpo-
rate the effect of proposed interventions into the base model and
simulate expected long-term outcomes of early intervention. This
not only gives feedback to researchers about the utility of their pre-
ventive actions; but it provides a motivation to target transitions in
a model where an intervention will have the most signiﬁcant ef-
fect. Then, as studies are conducted, data may be used to calibrate
and correct the base model as the state of the science advances. To-
gether, these and other practical uses of the software will help
researchers comprehend complex disease processes. Making this
tool available freely and openly, facilitates disease modeling activ-
ities and therefore contributes to better understanding of disease
progression.
Not only can researchers beneﬁt from a disease modeling soft-
ware, we hope that in the future physicians can eventually use the1) for a few individuals. Time 0 means the initial baseline population as generated by
t state during a certain time step. Note that entering a state raises the _Entered state
ngina_
ntered
Angina No_
Retinopathy
Non_Proliferative_
Entered
Non_
Proliferative
(A total
of 111
parameters)
0 1 0 0 . . .
0 1 0 0 . . .
0 1 0 0 . . .
0 0 1 1 . . .
0 0 0 1 . . .
0 0 0 1 . . .
0 0 0 1 . . .
0 0 0 0 . . .
0 0 0 0 . . .
0 0 0 0 . . .
0 0 0 0 . . .
0 1 0 0 . . .
0 0 1 1 . . .
0 0 0 1 . . .
0 0 0 1 . . .
0 0 0 0 . . .
1 0 0 0 . . .
1 0 0 0 . . .
1 0 0 0 . . .
1 0 0 0 . . .
1 0 0 0 . . .
1 0 0 0 . . .
. . . . . . . . . . . . . . . . .
0 1 0 0 . . .
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cian can simulate patient outcomes based on the demographic
characteristics of a speciﬁc patient, for a variety of proposed treat-
ment plans. In this manner, a patient can become a more active
participant in his or her own health care decisions.
Our web site also contains additional information on the pro-
ject, beyond the published software and diabetes model. The web
site can be accessed online at: http://www.med.umich.edu/
mdrtc/cores/DiseaseModel/.
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Appendix A
This appendix shows the Michigan model for diabetes raw sim-
ulation output. It is representative of output results typically gen-
erated by our software framework. Table 3 demonstrates a sample
of this raw output for a single simulation repetition. Due to the size
of the table, only part of the information is shown. This raw infor-
mation was analyzed by tools provided with our software frame-
work to create the results in Table 2.
References
[1] Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic
evaluation of health technologies. Health Econ 2006;15:1295–310.
doi:10.1002/hec.1148.
[2] Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C,
et al. Principles of good practice for decision analytic modeling in health-care
evaluation: report of the ISPOR Task Force on Good Research Practices –
Modeling Studies. Value Health 2004;6:9–17. American Diabetes Association
Consensus Panel 2004), Guidelines for computer modeling of diabetes and its
complications (Consensus Statement), Diabetes Care 27 2262-2265.
[3] American Diabetes Association Consensus Panel. Guidelines for computer
modeling of diabetes and its complications (Consensus Statement). Diabetes
Care 2004;27:2262–5.
[4] The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its
complications: a report on the Fourth Mount Hood Challenge Meeting.
Diabetes Care 2007;30:1638–46. doi:10.2337/dc07-9919.[5] Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes.
Diabetes Care 2003;26(11):3093–101.
[6] Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care
systems: the mathematical formulation. J Biomed Inform 2002;35:37–50.
doi:10.1016/S1532-046402)00006-0.
[7] Eddy DM, Schlessinger L. Validation of the Archimedes diabetes model.
Diabetes Care 2003;26(11):3102–10. doi:10.2337/diacare.26.11.3102.
[8] The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive
glycemic control, intensiﬁed hypertension control, and serum cholesterol level
reduction for type 2 diabetes. JAMA 2002;287(19):2542–51. doi:10.1001/
jama.287.19.2542.
[9] Hoerger TJ, Hicks KA, Bethke AD. A Markov model of disease progression and
cost-effectiveness for Type 2 diabetes. Technical Report, RTI health, social, and
economics research, funded by centers for disease control and prevention;
2004.
[10] Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, Mathieu
C, et al. Development and validation of the economic assessment of glycemic
control and long-term effects of diabetes (EAGLE) model. Diabetes Technol
Ther 2006;8(2):219–36. doi:10.1089/dia.2006.8.219.
[11] Eagle Diabetes Simulation Model, Version 2.0. Economic assessment of
glycemic control and long term effects, Technical Documentation, February
2005, Analytica International GmbH.
[12] Brown JB, Russell A, Chan W, Pedula P, Aickin M. The global diabetes model:
user friendly version 3.0. Diabetes Research and Clinical Practice Volume 50,
(Suppl. 3) (2000) S15–S46. doi: 10.1016/S0168-8227(00)00215-1.
[13] Clarke PM, Gray AM, Briggs A, Farmer A, Fenn P, Stevens R, et al. A model to
estimate the lifetime health outcomes of patients with type 2 diabetes: the
United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model
(UKPDS 68). Diabetologia 2004;47:1747–59. doi:10.1007/s00125-004-1527-z.
[14] Herman WH. Diabetes modeling. Diabetes Care 2003;26:3182–3.
[15] Zhou H, Isaman DJM, Messinger S, Brown MB, Klein R, Brandle M, et al. A
computer simulation model of diabetes progression quality of life and cost.
Diabetes Care 2002;28(12):2856–63.
[16] UKPDS UK Prospective Diabetes Study UKPDS Group. Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional treatment
and risk of complications in patients with type 2 diabetes UKPDS 33. Lancet
1998;352:837–53. doi:10.1016/S0140-673698)07019-6.
[17] Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. Risk of
stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk
engine (UKPDS 60). Stroke 2002;33:1776–81. doi:10.1161/
01.STR.0000020091.07144.C7.
[18] Isaman DJM, Barhak J, Ye W. Indirect estimation of a discrete-state discrete-
time model using secondary data analysis of regression data. Stat Med
2009;28(16):2095–115. doi:10.1002/sim.3599.
[19] Isaman DJM, Herman WH, Brown MB. A discrete-state and discrete-time
model using indirect estimates. Stat Med 2006;25:1035–49. doi:10.1002/
sim.2241.
[20] Byrd RH, Lu P, Nocedal J. A limited memory algorithm for bound constrained
optimization. SIAM J Sci Stat Comput 1995;16(5):1190–208.
[21] Zhu C, Byrd RH, Nocedal J. L-BFGS-B: algorithm 778: L-BFGS-B FORTRAN
routines for large scale bound constrained optimization. ACM Trans Math
Software 1997;23(4):550–60.
[22] Diabetes PHD. Online, Accessed on March 25, 2010: Available from: http://
www.diabetes.org/living-with-diabetes/complications/diabetes-phd/.
[23] Ginsberg J, Mohebbi MH, Patel RS, Brammer L, Smolinski MS, Brilliant L.
Detecting inﬂuenza epidemics using search engine query data. Nature
2009;457:1012–4. doi:10.1038/nature07634.
[24] Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L.
Forecasting coronary heart disease incidence mortality and cost: the Coronary
Heart Disease Policy Model. Am J Public Health 1987;77(11):1417–26.
[25] Urban N, Drescher C, Etzioni R, Colby C. Use of a stochastic simulation model to
identify an efﬁcient protocol for ovarian cancer screening. Control Clin Trials
1997;18(3):251–70. doi:10.1016/S0197-2456. 96)00233-4.
